Data/hora: 09/06/2024 14:46:42

Provedor de dados: | 5
País: | France
Título: | Effect of an oversulfated exopolysaccharide on angiogenesis induced by fibroblast growth factor-2 or vascular endothelial growth factor in vitro
Autores: | Matou, Sabine; Colliec-jouault, Sylvia; Galy Fauroux, Isabelle; Ratiskol, Jacqueline; Sinquin, Corinne; Guezennec, Jean; Fischer, Anne-marie; Helley, Dominique.
Data: | 2005-03
Ano: | 2005
Palavras-chave: | Matrigel; Collagen gel; Alpha 6 integrin subunit; Angiogenic growth factor; Polysaccharide; Angiogenesis.
Resumo: | The aim of this study was to determine the angiogenic properties of an oversulfated exopolysaccharide (OS-EPS) derived from a polysaccharide secreted by the mesophilic bacterium Alteromonas infernus. We compared the effect of this OS-EPS with that of a non-oversulfated exopolysaccharide (EPS) on human umbilical vein endothelial cell (HUVEC) proliferation, migration and differentiation induced by basic fibroblast growth factor (FGF-2) or vascular endothelial growth factor (VEGF). OS-EPS enhanced HUVEC proliferation by 58% when used alone, and by respectively 30% and 70% in the presence of FGF-2 and VEGF. OS-EPS also increased the density of tubular structures on Matrigel in the presence of FGF-2 or VEGF. Vascular tube fort-nation was related to alpha(6) integrin subunit expression, which was enhanced by 50% in the presence of the growth factors. Indeed, a monoclonal anti-alpha(6) blocking antibody abolished this vascular tube formation. EPS had no effect in any of the experimental conditions, underlying the importance of sulfation in the angiogenic effects of exopolysaccharide. By potentiating the angiogenic activity of FGF-2 and/or VEGF, OS-EPS, which possesses low anticoagulant activity and thus a low hemorrhagic risk, could potentially be used to accelerate vascular wound healing or to promote the growth of collateral blood vessels in ischemic tissues. (C) 2004 Elsevier Inc. All rights reserved.
Tipo: | Text
Idioma: | Inglês

Identificador:

http://archimer.ifremer.fr/doc/2005/publication-2118.pdf

DOI:10.1016/j.bcp.2004.11.021

Editor: | Elsevier
Relação: | http://archimer.ifremer.fr/doc/00000/2118/
Formato: | application/pdf
Fonte: | Biochemical Pharmacology (0006-2952) (Elsevier), 2005-03 , Vol. 69 , N. 5 , P. 751-759
Fonte: | 2004 Elsevier Inc. All rights reserved.